Faisal Khurshid
Stock Analyst at Leerink Partners
(3.24)
# 1,024
Out of 4,959 analysts
23
Total ratings
55.56%
Success rate
2.8%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $0.89 | +123.54% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $101.68 | +0.31% | 2 | Jul 10, 2025 | |
| ABCL AbCellera Biologics | Assumes: Outperform | $5 | $4.30 | +16.28% | 1 | Jul 7, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $1.18 | -15.25% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $16.78 | +168.18% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $9.65 | +65.89% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.45 | +37.93% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $4.95 | +223.23% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $42.52 | +41.11% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $91.14 | -12.22% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.99 | +653.77% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $7 | $7.49 | -6.54% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $18.77 | +139.74% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $31.95 | -24.88% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.43 | +389.51% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $3.94 | +103.05% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.94 | +429.16% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $3.23 | +240.56% | 1 | Mar 21, 2023 |
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $0.89
Upside: +123.54%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $101.68
Upside: +0.31%
AbCellera Biologics
Jul 7, 2025
Assumes: Outperform
Price Target: $5
Current: $4.30
Upside: +16.28%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $1.18
Upside: -15.25%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $16.78
Upside: +168.18%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $9.65
Upside: +65.89%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.45
Upside: +37.93%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $4.95
Upside: +223.23%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $42.52
Upside: +41.11%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $91.14
Upside: -12.22%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.99
Upside: +653.77%
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $7.49
Upside: -6.54%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $18.77
Upside: +139.74%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $31.95
Upside: -24.88%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.43
Upside: +389.51%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $3.94
Upside: +103.05%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.94
Upside: +429.16%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $3.23
Upside: +240.56%